Clinical trial
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants…
NCT05147220 · Novartis Pharmaceuticals, Industry · Active, not recruiting
Key facts
| NCT number | NCT05147220 |
|---|---|
| Title | Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) |
| Official title | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib |
| Acronym | REMODEL-1 |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Relapsing Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Remibrutinib, Teriflunomide |
| Enrollment | 1,001 |
| Start date | Dec 16, 2021 |
| Primary completion | Apr 30, 2026 |
| Completion | Oct 30, 2030 |
| First posted | Dec 7, 2021 |
| Last update posted | Feb 3, 2026 |
| Countries | Argentina, Austria, Belgium, Brazil, Bulgaria, Chile, China, Colombia, Croatia, Denmark, Georgia, Guatemala and 22 more |
At a glance
- 100–999 Study sites
- No Results posted
- 10–99 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: